Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1944 1
1945 3
1959 2
1960 2
1961 1
1962 2
1963 1
1964 4
1965 1
1966 1
1967 1
1968 1
1969 5
1970 1
1971 1
1972 1
1973 5
1974 5
1975 3
1976 10
1977 4
1978 4
1979 3
1981 1
1982 3
1983 4
1984 2
1985 9
1986 2
1987 4
1988 3
1990 1
1991 3
1992 1
1993 6
1994 1
1995 2
1996 2
1997 5
1998 2
1999 1
2000 3
2001 5
2003 1
2004 4
2005 5
2006 4
2007 2
2008 6
2009 4
2010 1
2011 2
2012 1
2013 6
2014 14
2015 7
2016 3
2017 5
2018 6
2019 4
2020 9
2021 8
Text availability
Article attribute
Article type
Publication date

Search Results

196 results
Results by year
Filters applied: . Clear all
Page 1
Dl-phenylalanine in depressed patients: an open study.
Beckmann H, Strauss MA, Ludolph E. Beckmann H, et al. J Neural Transm. 1977;41(2-3):123-34. doi: 10.1007/BF01670277. J Neural Transm. 1977. PMID: 335027 Clinical Trial.
In an open study dl-phenylalanine in doses from 75-200 mg/day was administered to 20 depressed patients for 20 days. ...It is concluded that dl-phenylalanine might have substantial antidepressant properties and that further more controlled investigatio …
In an open study dl-phenylalanine in doses from 75-200 mg/day was administered to 20 depressed patients for 20 days. ...It is …
DL-phenylalanine versus imipramine: a double-blind controlled study.
Beckmann H, Athen D, Olteanu M, Zimmer R. Beckmann H, et al. Arch Psychiatr Nervenkr (1970). 1979 Jul 4;227(1):49-58. doi: 10.1007/BF00585677. Arch Psychiatr Nervenkr (1970). 1979. PMID: 387000 Clinical Trial.
In a double-blind study, DL-phenylalanine (150--200 mg/24 h) or imipramine (150--200 mg/24 h) was administered to 40 depressed patients (20 patients in each group) for 30 days. ...Separate analysis of psychopathological syndromes as somatic depressive syndrome and r …
In a double-blind study, DL-phenylalanine (150--200 mg/24 h) or imipramine (150--200 mg/24 h) was administered to 40 depressed …
Metabolism of DL-(+/-)-phenylalanine by Aspergillus niger.
Kishore G, Sugumaran M, Vaidyanathan CS. Kishore G, et al. J Bacteriol. 1976 Oct;128(1):182-91. doi: 10.1128/jb.128.1.182-191.1976. J Bacteriol. 1976. PMID: 10273 Free PMC article.
A fungus capable of degrading DL-phenylalanine was isolated from the soil and identified as Aspergillus niger. It was found to metabolize DL-phenylalanine by a new pathway involving 4-hydroxymandelic acid. ...
A fungus capable of degrading DL-phenylalanine was isolated from the soil and identified as Aspergillus niger. It was found to …
4-Chloro-DL-phenylalanine protects against monocrotaline-induced pulmonary vascular remodeling and lung inflammation.
Bai Y, Wang HM, Liu M, Wang Y, Lian GC, Zhang XH, Kang J, Wang HL. Bai Y, et al. Int J Mol Med. 2014 Feb;33(2):373-82. doi: 10.3892/ijmm.2013.1591. Epub 2013 Dec 16. Int J Mol Med. 2014. PMID: 24337018
The present study was performed to investigate the effects of 4-chloro-DL-phenylalanine (PCPA), a tryptophan hydroxylase (Tph) inhibitor (TphI), on pulmonary vascular remodeling and lung inflammation in monocrotaline (MCT)-induced pulmonary arterial hypertension (PA …
The present study was performed to investigate the effects of 4-chloro-DL-phenylalanine (PCPA), a tryptophan hydroxylase (Tph) …
DL-phenylalanine markedly potentiates opiate analgesia - an example of nutrient/pharmaceutical up-regulation of the endogenous analgesia system.
Russell AL, McCarty MF. Russell AL, et al. Med Hypotheses. 2000 Oct;55(4):283-8. doi: 10.1054/mehy.1999.1031. Med Hypotheses. 2000. PMID: 10998643
In the author's clinical experience, concurrent treatment with DL-phenylalanine (DLPA) often appears to potentiate pain relief and also ease depression in patients receiving opiates for chronic non-malignant pain. ...Since serotonin and enkephalins are key neurotran …
In the author's clinical experience, concurrent treatment with DL-phenylalanine (DLPA) often appears to potentiate pain relief …
Enhancement of bioavailability of cinnarizine from its beta-cyclodextrin complex on oral administration with DL-phenylalanine as a competing agent.
Tokumura T, Nanba M, Tsushima Y, Tatsuishi K, Kayano M, Machida Y, Nagai T. Tokumura T, et al. J Pharm Sci. 1986 Apr;75(4):391-4. doi: 10.1002/jps.2600750415. J Pharm Sci. 1986. PMID: 3723361
The enhancement of AUC and Cmax completely depended on the dose of DL-phenylalanine. It was found from these results that DL-phenylalanine acted as a competing agent in the GI tract and the minimum effective dose required of DL-phenylalanine
The enhancement of AUC and Cmax completely depended on the dose of DL-phenylalanine. It was found from these results that D
Treatment of attention deficit disorder with DL-phenylalanine.
Wood DR, Reimherr FW, Wender PH. Wood DR, et al. Psychiatry Res. 1985 Sep;16(1):21-6. doi: 10.1016/0165-1781(85)90024-1. Psychiatry Res. 1985. PMID: 3903813 Clinical Trial.
Nineteen patients meeting the criteria for attention deficit disorder, residual type (adult hyperactivity), were given a 2-week double-blind crossover of DL-phenylalanine versus placebo. Thirteen subjects completed the study; the mean global rating of improvement ap …
Nineteen patients meeting the criteria for attention deficit disorder, residual type (adult hyperactivity), were given a 2-week double-blind …
196 results